WELLS FARGO SECURITIES, LLC (“Agent”)Letter Agreement • August 28th, 2012 • Wright Medical Group Inc • Orthopedic, prosthetic & surgical appliances & supplies • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Wright Medical Group, Inc. (“Company”) to Wells Fargo Bank, National Association (“Dealer”), through its agent Wells Fargo Securities, LLC (the “Agent”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
WELLS FARGO SECURITIES, LLC (“Agent”)Wright Medical Group Inc • August 28th, 2012 • Orthopedic, prosthetic & surgical appliances & supplies • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Wells Fargo Bank, National Association (“Dealer”), through its agent Wells Fargo Securities, LLC (the “Agent”) and Wright Medical Group, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
WRIGHT MEDICAL GROUP, INC. Purchase AgreementPurchase Agreement • August 28th, 2012 • Wright Medical Group Inc • Orthopedic, prosthetic & surgical appliances & supplies • New York
Wright Medical Group, Inc., a Delaware corporation (herein called the “Company” which term shall include its direct and indirect subsidiaries unless the context otherwise requires), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the “Representative”), $260,000,000 principal amount of its 2.00% Cash Convertible Senior Notes due 2017 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $40,000,000 principal amount of its 2.00% Cash Convertible Senior Notes due 2017 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 2.00% Cash Convertible Senior Notes due 2017 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be issued pursuant
